Kahwash Rami, Kikta Donald, Khayat Rami
Division of Cardiovascular Medicine, Section of Heart Failure and Transplant, Davis Heart/Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210, USA.
Curr Heart Fail Rep. 2011 Mar;8(1):72-9. doi: 10.1007/s11897-010-0037-1.
It is increasingly recognized that sleep-disordered breathing (SDB) is a common modifiable risk factor for cardiovascular disease with significant impact on morbidity and potentially mortality. SDB is highly prevalent in patients with systolic or diastolic heart failure. A high index of suspicion is necessary to diagnose SDB in patients with heart failure because the vast majority of affected patients do not report daytime symptoms. Recent clinical trials have demonstrated improvement in heart function, exercise tolerance, and quality of life after treatment of SDB in patients with heart failure. Accumulating evidence suggests that treatment of SDB should complement the established pharmacologic therapy for chronic heart failure. However, mortality benefit has yet to be demonstrated.
人们越来越认识到，睡眠呼吸紊乱（SDB）是心血管疾病常见的可改变风险因素，对发病率甚至潜在死亡率都有重大影响。SDB在收缩期或舒张期心力衰竭患者中非常普遍。由于绝大多数受影响患者没有报告白天症状，因此对心力衰竭患者诊断SDB需要高度怀疑。最近的临床试验表明，心力衰竭患者治疗SDB后，心脏功能、运动耐量和生活质量都有所改善。越来越多的证据表明，SDB的治疗应补充既定的慢性心力衰竭药物治疗。然而，尚未证明其对死亡率有改善作用。
